18 patients (85.7%) improved with UDCA only within a median of 36 days (5-168)
Shenuarin Bhuiyan: Nothing to Disclose, Gretchen Galliano: Nothing to Disclose, Bo Wei: Nothing to Disclose, Lin Tan: Nothing to Disclose, Iqbal Mahmud: Nothing to Disclose, Ida Surakka: Nothing to Disclose, Minerva Garcia-Barrio: Nothing to Disclose, Philip Lorenzi: Nothing to Disclose, Eyal Gottlieb: Nothing to Disclose, Eduardo Salido: Nothing to Disclose, Jifeng Zhang: Nothing to Disclose, Wayne Orr: Nothing to Disclose, Wanqing Liu: Nothing to Disclose, Monica Diaz-Gavilan: Nothing to Disclose, Eugene Chen: Nothing to Disclose, Nirav Dhanesha: Nothing to Disclose, Paul Thevenot: Boston Scientific: Grant/Research Support, FUJIFILM: Grant/Research Support, Helio Genomics: Grant/Research Support, Ari Cohen: Nothing to Disclose, Arif Yurdagul: Nothing to Disclose 1642 A SMALL MOLECULE INHIBITOR OF FIBROBLAST ACTIVATION PROTEIN (FAP) BLOCKS ENZYMATIC ACTIVITY AND IMPROVES LIVER HISTOPATHOLOGY IN CYNOMOLGUS MONKEYS WITH MASH AND F1/F2 FIBROSIS Xiao-Rong Peng 1 Mathias Liljeblad 2 David Janzn 2 Tasso Miliotis 2 Eva Tppner Carlsson 2 Jianming Liu 2 Peter Konings 2 Magnus Sderberg 2 Anne-Christine Andrasson 2 Jens Petersen 2 Anneli Nordqvist 2 Mahssa Karimi 2 , 1 BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 2 BioPharmaceuticals R&D, AstraZeneca Background: Fibrosis severity is associated with liver-related outcomes and mortality for metabolic dysfunction-associated steatohepatitis (MASH)
However, it is possible that the underlying cause of some cases of malignant and hemorrhagic smallpox resulted from defective immune responses
Time is the main factor after alcohol is absorbed
